Skip to main content
. Author manuscript; available in PMC: 2017 May 5.
Published in final edited form as: Mol Cell Endocrinol. 2016 Feb 19;426:113–124. doi: 10.1016/j.mce.2016.02.015

Fig. 1.

Fig. 1

A transgene construct (A) consisting of a gonadotrope-specific ovine Fshb promoter driving the expression of a double N-glycosylation site mutant hFSHβ subunit-encoding cDNA-SV40 polyA sequences was engineered and microinjected into one-cell mouse embryos to produce transgenic mice. Genomic PCR assay of tail DNA samples (B) using oFshb promoter-specific primers (indicated by arrows in A) amplified a 750 bp fragment that identified and distinguished founder mice carrying the transgene (+) from control wild-type (WT), transgene-negative mice. A two-step genetic rescue scheme (C) was employed to produce the desired Fshb null mice carrying the HFSHBWT or HFSHBdgc transgene (Tg+).